Tong Ren Tang Technologies Co (HKSE:01666) ROCE % : 9.49% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Tong Ren Tang Technologies Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tong Ren Tang Technologies Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 9.49%.

Tong Ren Tang Technologies Co ROCE % Historical Data

The historical data trend for Tong Ren Tang Technologies Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tong Ren Tang Technologies Co ROCE % Chart

Tong Ren Tang Technologies Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

11.20

11.85

12.76

12.38

11.06

Tong Ren Tang Technologies Co Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															11.27	12.11	13.42	12.69	9.49

Tong Ren Tang Technologies Co ROCE % Calculation

Tong Ren Tang Technologies Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1325.366	/	( ( (13941.924 - 2291.1)	+	(14774.483 - 2448.845) )	/ 2 )
	=	1325.366	/	( (11650.824	+	12325.638)	/ 2 )
	=	1325.366	/	11988.231
	=	11.06 %

Tong Ren Tang Technologies Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	1152.432	/	( ( (14306.904 - 2347.485)	+	(14774.483 - 2448.845) )	/ 2 )
	=	1152.432	/	( ( 11959.419	+	12325.638 )	/ 2 )
	=	1152.432	/	12142.5285
	=	9.49 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Tong Ren Tang Technologies Co (HKSE:01666) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tong Ren Tang Technologies Co ROCE % Related Terms

Thank you for viewing the detailed overview of Tong Ren Tang Technologies Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tong Ren Tang Technologies Co (HKSE:01666) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tong Ren Tang Technologies Co Ltd (HKSE:01666) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TGRNF:USA TNG:Germany

Address

No. 16 Tongji Beilu, Beijing Economic and Technological Development Zone, Beijing, CHN

Website

https://www.tongrentangkj.com

Tong Ren Tang Technologies Co Ltd is engaged in the production and distribution of Chinese medicine and primarily operates in Mainland China and Hong Kong. The operating segments derive their revenue primarily from the manufacture and sale of Chinese medicine of the company in Mainland China and Tong Ren Tang Chinese Medicine and its subsidiaries engaged in manufacturing, retail, and wholesale of Chinese medicine products and healthcare products, and provision of Chinese medical consultation and treatments outside Mainland China and wholesale of healthcare products in Mainland China.

Executives

Citigroup Inc.	2502 Approved lending agent
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Aberdeen Asset Management Plc And Its Associates	2102 Investment manager

Tong Ren Tang Technologies Co (HKSE:01666) Headlines

No Headlines